Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MURA
stocks logo

MURA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.370
-81.59%
--
--
-0.810
-58.03%
--
--
-0.860
-51.29%
Estimates Revision
The market is revising No Change the revenue expectations for Mural Oncology plc (MURA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -1.45%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-1.45%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Mural Oncology PLC (MURA.O) is -1.19, compared to its 5-year average forward P/E of -0.64. For a more detailed relative valuation and DCF analysis to assess Mural Oncology PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.64
Current PE
-1.19
Overvalued PE
-0.33
Undervalued PE
-0.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.82
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.48
Undervalued EV/EBITDA
0.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.08
Current PS
0.00
Overvalued PS
0.64
Undervalued PS
-0.47
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 385.39% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

MURA News & Events

Events Timeline

(ET)
2025-11-26
09:04:43
Mural Oncology Reveals Final Cash Payment Due Upon Acquisition Completion
select
2025-10-24 (ET)
2025-10-24
16:29:41
Mural Oncology Shareholders Give Green Light to XRA 5 Corp. Acquisition
select
2025-08-20 (ET)
2025-08-20
08:35:20
XRA 5 Corp. to Purchase Mural Oncology for $2.035-$2.24 per Share in Cash
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-04Globenewswire
Mural Oncology to be Acquired by XOMA Royalty, Effective December 5, 2025
  • Acquisition Approval: The High Court of Ireland has sanctioned the scheme of arrangement between Mural Oncology and its shareholders, allowing XRA 5 Corp. to acquire all issued shares of Mural, which is expected to enhance liquidity for Mural's shareholders by providing cash compensation effective December 5, 2025.
  • Transaction Timeline: Mural shares are expected to cease trading on Nasdaq on December 4, 2025, with cash compensation distribution to shareholders anticipated to be completed by December 19, ensuring prompt access to funds and boosting shareholder confidence post-transaction.
  • Legal Compliance: The acquisition adheres to Chapter 1 of Part 9 of the Irish Companies Act, ensuring the legality and transparency of the transaction, which mitigates potential legal risks and enhances market trust in Mural's future prospects.
  • Market Reaction Anticipation: As the acquisition progresses, market interest in Mural is expected to rise, potentially attracting more investors to XOMA Royalty's strategic positioning, thereby further strengthening its market position in the biopharmaceutical sector.
[object Object]
Preview
8.5
12-04Newsfilter
Mural Oncology to be Acquired by XOMA Royalty, Effective December 5, 2025
  • Acquisition Scheme Approved: The High Court of Ireland has sanctioned the arrangement scheme between Mural and its shareholders, whereby XRA 5 Corp. will acquire all issued shares of Mural, with the transaction expected to become effective on December 5, 2025, marking a new investment opportunity for Mural's shareholders.
  • Transaction Timeline: Mural shares are expected to cease trading on Nasdaq on December 4, 2025, with the Court Order to be delivered to the Irish Registrar on December 5, ensuring a smooth transaction process that reflects the company's strategic adjustments in the capital markets.
  • Cash Distribution Plan: Under the scheme, XRA 5 Corp. will pay cash consideration to Mural shareholders, with distributions expected to commence shortly after the effective date and all payments to be completed by December 19, 2025, ensuring timely returns for shareholders.
  • Legal Compliance: The acquisition adheres to Irish takeover rules, with Mural's board accepting responsibility for the accuracy of the information, enhancing transparency and compliance, which bolsters investor confidence and maintains the company's reputation.
[object Object]
Preview
8.5
11-28NASDAQ.COM
Mural Oncology Shareholders Set to Receive $2.035 Cash for Each Share in XOMA Royalty Deal

  • Acquisition Details: Mural Oncology plc will receive a final cash consideration of $2.035 per share from XOMA Royalty Corporation upon closing of their acquisition, as per the Transaction Agreement signed on August 20, 2025.

  • Regulatory Process: The acquisition will be executed through an Irish High Court-sanctioned scheme of arrangement and is expected to close in early December 2025, pending court approval and satisfaction of remaining conditions.

  • Company Focus: Mural Oncology is dedicated to advancing immune-oncology therapies, including programs for nemvaleukin alfa, IL-18, and IL-12.

  • Stock Performance: MURA shares closed at $2.02, down 3.49%, with significant trading volume, and have fluctuated between $0.95 and $4.74 over the past year.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Mural Oncology PLC (MURA) stock price today?

The current price of MURA is 2.04 USD — it has increased 0 % in the last trading day.

arrow icon

What is Mural Oncology PLC (MURA)'s business?

Mural Oncology plc is Ireland-based clinical-stage oncology company. The Company is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. The lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational-engineered cytokine fusion protein that selectively binds to the intermediate-affinity interleukin-2 (IL-2) receptor. The Company has also developed engineered therapies targeting the interleukin-18 (IL-18) and interleukin-12 (IL-12) pathways, which have demonstrated therapeutic potential in third-party preclinical and clinical studies.

arrow icon

What is the price predicton of MURA Stock?

Wall Street analysts forecast MURA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MURA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Mural Oncology PLC (MURA)'s revenue for the last quarter?

Mural Oncology PLC revenue for the last quarter amounts to -3.97M USD, decreased -88.37 % YoY.

arrow icon

What is Mural Oncology PLC (MURA)'s earnings per share (EPS) for the last quarter?

Mural Oncology PLC. EPS for the last quarter amounts to -18481000.00 USD, decreased -38.59 % YoY.

arrow icon

What changes have occurred in the market's expectations for Mural Oncology PLC (MURA)'s fundamentals?

The market is revising No Change the revenue expectations for Mural Oncology plc (MURA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -1.45%.
arrow icon

How many employees does Mural Oncology PLC (MURA). have?

Mural Oncology PLC (MURA) has 116 emplpoyees as of December 05 2025.

arrow icon

What is Mural Oncology PLC (MURA) market cap?

Today MURA has the market capitalization of 35.38M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free